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Commentary
The two most common congenital bleed-
ing disorders are von Willebrand disease
(VWD) and hemophilia.  VWD is caused by
the defective synthesis or function of a pro-
tein, von Willebrand factor that is necessary
for normal blood clotting.  VWD occurs with
equal frequency in males and females.  Al-
though the prevalence of this disease is not
precisely known, it is estimated that between
one and two percent of the population are
affected.  There are different types and sever-
ity of VWD. Symptoms include heavy or
prolonged menstrual bleeding, easy bruising,
frequent or prolonged nosebleeds, and pro-
longed bleeding following surgery, dental
work, childbirth, or injury.
  Hemophilia is caused by a defect in the
gene located on the X chromosome that
contains the genetic code for one of the
clotting factor proteins necessary for normal
blood clotting.  A deficiency of factor VIII is
referred to as hemophilia A or “classic”
 hemophilia.  In contrast, a deficiency of factor
IX characterizes hemophilia B, also known as
Christmas disease.  The defect usually occurs
on one of the two female X chromosomes and
results in a carrier state.  When males have
the defect on their only X chromosome, they
have the disease.  Thus, almost all of the
approximately 17,000 people with hemophilia
in the United States are male.
  People with severe hemophilia can
 experience serious bleeding into tissues,
muscles, joints, and internal organs, often
without any obvious trauma.  Repeated
bleeding into joints without adequate
treatment results in crippling chronic joint
disease, one of the severe complications of
bleeding disorders.  In the mid-1970s, treat-
ment for hemophilia was improved through
the use of clotting factor concentrates,
products made from the plasma of donated
blood.  However, because blood donations
from thousands of donors are pooled together
to make these products, many people with
bleeding disorders were infected with
hepatitis B and C viruses and with human
immunodeficiency virus (HIV), the virus that
causes AIDS, before the risk of disease
transmission in blood products was
recognized and prevention measures taken.
  In 1975, Congress initiated federal funding
to specialized hemophilia treatment centers
(HTCs) to provide comprehensive care to
people with bleeding disorders.  Since 1986,
the Centers for Disease Control and
Prevention (CDC) has been involved with the
hemophilia community through the HTC
system, primarily through risk-reduction efforts
aimed at preventing secondary infection of
family members with HIV.
  In 1991, CDC received a request from the
National Hemophilia Foundation to expand
their collaborative activities within the
bleeding disorders community.  Meetings with
patients and hemophilia care providers were
held during 1992 to determine the areas of
highest priority.  Based on recommendations
from these constituents, a congressional
mandate was issued to CDC, with the goal of
reducing the human suffering and financial
burden of bleeding disorders by focusing
national emphasis on prevention and early
intervention.  The issues of greatest concern
identified by the bleeding disorders
community were: (1) the safety of the blood
supply from infectious diseases and (2) the
prevention of joint disease.
  In response, CDC developed the Universal
Data Collection Program (UDC).  The
purpose of UDC is two-fold: (1) to establish a
sensitive blood safety monitoring system
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among people with bleeding disorders and
(2) to collect a uniform set of clinical
outcomes information that can be used to
monitor the occurrence of and potential risk
factors for infectious diseases and joint
complications.
  People with bleeding disorders are enrolled
in UDC by care providers in each of the
nation’s 134 federally funded HTCs.  As part
of the project, a uniform set of clinical data
and plasma specimens is collected by HTC
staff each year during each participant’s
annual comprehensive clinic visit.   A portion
of the plasma specimen is used to perform
free screening tests for hepatitis A, B, and C
viruses and for HIV.  The remainder of the
specimen is stored for use as needed in
future blood safety investigations.
  Enrollment in UDC began in May 1998.
Information about eligibility requirements,
enrollment procedures, and data collection
can be found in the Technical Notes of this
report.  Participating HTCs are listed by
region in the Acknowledgements.  A regional
map is included at the end of this report.
  The purpose of this surveillance report is to
disseminate the information being collected
by UDC to public health workers, health
educators and planners, other care providers,
and patients in the bleeding disorders
community.  The report contains information
about the demographic characteristics of the
participants, their blood and factor product
use, and the occurrence and treatment of joint
and infectious diseases.
  We hope that this information will prove
useful to those involved in efforts to reduce or
prevent the complications of these conditions.
The proper interpretation and appropriate
use of surveillance data require an
understanding of how the data are collected,
reported, and analyzed.  Therefore, readers
of this report are encouraged to review the
Technical Notes, beginning on page 18.
Highlights
This issue of the UDC Surveillance Report is
a special report that focuses on data col-
lected from children under two years of age
(babies) who have been enrolled through
September 2005.  Data collection on this
group began its pilot phase in April 2003.
The data collected on these initial 38 babies
is included in this report. The pilot phase ran
through April 2004.   Official enrollment of
babies into UDC began in May 2004 and
continues.  In this report, data on enrollment
and visits (Tables 1 and 2, Figure 1) include
all babies seen through September 2005.
However, all subsequent tables and graphs
describe the hemophilia population only.
Since April, 2003, 220 babies with bleeding
disorders have been enrolled and there have
been 229 UDC visits.
Tables 1 and 2 show new enrollment in UDC.
211 and 7 babies with hemophilia and VWD
respectively have been enrolled.  In addition
2 with Factor VII deficiency were also enrolled
(data not shown). Enrollment has approxi-
mately doubled in each year, with 30 babies
in 2003, 55 in 2004, and 133 through
September 2005. (Table 1).  Table 2 shows
that regional enrollment has ranged from 1
in Region VII to as many as 40 babies in
Region VIII.
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Figure 1 shows the number of babies with a
UDC visit in each year through September
2005 according to visit type.  The number of
babies with a first time UDC visit is much
greater than those with a follow-up visit
because enrollment and data collection has
only recently begun and enough time has not
passed to adequately capture return visits.  In
the UDC population aged 2 years and over,
follow-ups visits outnumber first-time visits at
a ratio of approximately 3.5 to 1 over time.
The distribution of demographic characteris-
tics is shown in Table 3.  Just over half are 1
year or less and all are males. The population
distribution by race and ethnicity is similar to
that of the general population
Table 4 lists the sources of healthcare reim-
bursement. About 50% of participants have
some form of commercial insurance, about
40-45% have government sponsored cover-
age, and the remainder have other types of
insurance.  Only about 3-4% of the partici-
pants are uninsured.
Table 5 shows information on birth.  Almost
two-thirds of the babies were delivered
vaginally.  Instrumentation during delivery was
performed on 7 babies (3.3%).  There were
20 pre-term births (defined as less than 37
weeks at birth) and the mean age of these
was 34.7 weeks. Vitamin K was administered
almost two-thirds of the time.  Less than 10%
received clotting factor concentrate at birth
and then it was given either for prophylaxis or
treatment of a bleed.    An HTC was contacted
before delivery in only 32.5% of the cases.
Diagnostic testing is described in Table 6.
62% of babies enrolled, had hemophilia
diagnostic testing performed because the
mother was a known carrier or there was a
positive family history. In 34% of the babies , a
bleeding symptom prompted the diagnostic
testing.  The mean age of diagnosis was 18
days and almost 70% of the babies were
diagnosed before one month of age.  Seven
babies had prenatal testing performed, and
13.7% of participants had genetic
analysis for the hemophilia genetic mutation.
Figure 2 shows the distribution of disease
severity.  Over half of the babies had severe
disease, 27.5% had moderate disease and
16.1% had mild disease.
Table 7 show site of blood draw for factor
activity level that determines disease severity.
Over 70% had venipuncture as their site of
blood draw.
Table 8 shows that the most common type of
treatment used for all severity levels of
hemophilia was episodic care.  As expected,
babies with severe disease were the most
likely to be on continuous prophylaxis.
The proportion of overall factor product use is
shown in Table 9. The majority of babies with
hemophilia who require factor infusion are
administered recombinant products. About
25% of babies received no product during the
year prior to their UDC visit. Also of note is
that 8 babies received cryoprecipitate or
fresh frozen plasma, products which are not
as effective as clotting factor in treating
bleeds.
Table 10 illustrates that among the 158
babies receiving factor product, 22.8% are
home infused. Of these, two-thirds receive
their infusion from a family member.
Data on bleeding are shown in Tables 11. At
enrollment, 68.3% of babies had experienced
a bleed and the mean age of the first bleed
was 28.5 days. In nearly one-third of cases,
the first bleed occurred at the site of
circumcision. However, the sites with the
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most frequent bleeding episodes were the
soft tissues (79 participants), followed by oral/
nasal sites (57 participants).  Three babies
had long-term effects due to bleeding includ-
ing focal neurological deficits, seizure disor-
der and neuropathy due to compartment
syndrome.
Table 12 lists information on head injuries and
intracranial hemorrhages. A majority of
babies, 162/211 (76.8%) did not
experience a head injury since birth or last
UDC visit. Of the 49 babies who had a head
injury,  31 had one head injury, 11 had two,
and 7 had 3 or more. One of the head injuries
resulted in a skull fracture. Finally, 14 babies
had an intracranial hemorrhage (ICH).  The
most common site of ICH was subdural
(50%), followed by intracerebral (36.7%) and
subarachnoid (14.3%).  In most cases, ICH
was confirmed by computerized tomography
and ICH was found to be associated with
delivery at birth or
spontaneous occurrence in equal proportions.
Table 13 describes Hepatitis B vaccination
status and route of administration. More than
half of the babies had completed the basic
Hepatitis B vaccination series at UDC enroll-
ment and almost a third (29.9%) were cur-
rently receiving the series. Route of
administration was intramuscular in 23.7% of
babies, subcutaneous in 18.5%, and unknown
for 52.6%. The high proportion of unknown
administration route data reflects the fact that
most of the babies do not receive the vaccine
in the treatment center and the parents usually
do not know this information.
Table 14 describes the use of central venous
access devices for clotting factor infusion. At
the latest visit, 11.4% of babies had had at
least one CVAD placed since birth or the last
UDC visit and, of these, 79.1% were ports. Of
those with a CVAD, 10 babies had at least
one CVAD complication. The most common
CVAD complication was infection, which
occurred in 8 of the 10 babies with a compli-
cation.
Table 15 shows the prevalence of inhibitors
among persons with hemophilia under age 2
enrolled in UDC. The majority of inhibitors
occurred in babies with hemophilia A and
severe disease and most of these inhibitors
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Table 1. New Enrollment in UDC, April 2003 -September 2005
















































First-time visit Follow-up visit 
n=34 n=62 n=133
 Figure 1.  UDC visits by year, April 2003-September 2005
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Table 3.  Demographic characteristics of children with hemophilia* < 2 years of
age enrolled in UDC
ailihpomeH
)851=n(A )35=n(B
citsiretcarahC rebmuN tnecreP rebmuN tnecreP
shtnom(puorGegA )
3-0 22 9.31 7 2.31
6-4 02 7.21 7 2.31
9-7 71 8.01 3 7.5
21-01 32 6.41 8 1.51
51-31 32 6.41 9 0.71
81-61 81 4.11 5 4.9
42-91 53 2.22 41 4.62
yticinhtE/ecaR
etihW 59 1.06 73 8.96
naciremAnacirfA 91 0.21 2 8.3
cinapsiH 13, 6.91 8 1.51
rednalsIcificaP/naisA 4 5.2 1 9.1
naciremAevitaN 2 3.1 0 0.0
rehtO 7 4.4 5 4.9
xeS
elaM 851 001 35 001
elameF 0 -- 0 --
*One person was reported to have both hemophilia and VWD (this person is included in analyses as a
hemophilia patient only and not as a VWD patient).  A total of 2 persons had Factor VII deficiency.













Table 4.  Sources* of health care reimbursement listed by children with
             hemophilia <2 years of age enrolled in UDC
*Some people may have listed more than one source of reimbursement.
 HMO = Health maintenance organization; PPO = Preferred provider organization
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Table 5.  Birth Information of children with hemophilia < 2 years of age enrolled in
                UDC
*More than one delivery method may be selected
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Table 6. Diagnostic testing on children with hemophilia < 2 years of age enrolled in
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Figure 2.   Disease severity of children with hemophilia < 2 years of
                   age enrolled in UDC
Table 7.  Site of blood draw for factor activity level in children with hemophilia < 2









Mild  (Factor Activity >5%)
Moderate (Factor Activity 1-5 %)
Severe (Factor Activity <1%)
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Table 8.  Treatment type for children with hemophilia < 2 years of age
                 enrolled in UDC
*Prophylaxis is considered continuous when clotting factor is administered on a regular basis to prevent all
bleeding and is expected to continue indefinitely.
dliM etaredoM ereveS
tnemtaerT rebmuN tnecreP rebmuN tnecreP rebmuN tnecreP
eraccidosipE 43 001 25 7.98 69 7.08
suounitnoC
sixalyhporP 0 -- 5 6.8 81 1.51
latoT 43 85 911
Table 9.  Blood and factor products used* by children with hemophilia <2 years of
                age enrolled in UDC
*Any use of the product(s) during the 12-month period preceding the UDC visit.
NOTE: Individuals may have used more than one type of treatment product.
AailihpomeH BailihpomeH
tcudorptnemtaerT rebmuN tnecreP rebmuN tnecreP
rotcaftnanibmoceR 801 4.86 63 9.76
IIIVrotcaflanolcnoM 0 -- 0 --
IIIVrotcafnamuhrehtO 4 5.2 0 --
IIIVrotcafenicroP 0 -- 0 --
XIrotcafnamuH 0 -- 1 9.1
xelpmocnibmorhtorP 0 -- 0 --
xelpmocnibmorhtorpdetavitcA 4 5.2 0 --
PFFfoetatipicerpoyrC 6 8.3 2 8.3
nisserpmoseD 1 6.0 0 --
racimA 91 3.21 9 0.71
desuenoN 93 7.42 41 4.62
Table 10. Home factor infusion in children with hemophilia < 2 years of age
                    enrolled in UDC
*Percent is out of total number of those receiving home infusion.  Indivdiuals may have more than one
method of home infusion.
rebmuN tnecreP
)851=n(noisufniemoH 63 8.22
:ybnevignoisufnI rebmemylimaF 42 7.66
redivorperaC 51 7.14
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Table 11. Bleeding in children with hemophilia <2 years of age enrolled in UDC
*Percent is out of those who reported ever having a bleed
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Table 12.   Head injuries and intracranial hemorrhages (ICH) in children with
                    hemophilia <2 years of age enrolled in UDC
*Percent is out of total number with head injuries
** More than one choice is possible and percent is out of total number of ICHs
rebmuN latoTfo%
tisivCDUtsalrohtribecnisseirujnidaeH
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Table 13.   Hepatitis B vaccination in children with hemophilia <2 years of age
                    enrolled in UDC
Table 14.   Central venous access devices (CVADs) in children with hemophilia < 2
                    years of age enrolled in UDC
*Percent is out of total number of babies with CVADs placed























19UDC Report Vol. 8, No 1Vol
Table  15.  Prevalence of current inhibitors by titer* among children with
                    hemophilia < 2 years of age enrolled in UDC
* Inhibitor titer is determined by the highest reported inhibitor titer for any visit.
  Low titer is defined as an inhibitor level of 0.5 - 5 Bethesda units (BU).
  High titer is defined as an inhibitor level of >5 BU.
AailihpomeH BailhpomeH
ytireveS rebmuN retitwoL retithgiH rebmuN retitwoL retiThgiH
dliM 92 0 000.00 0 00.00 5 0 00.00 0 00.00
etaredoM 43 )%8.8(3 0 00.00 42 )%2.4(1 0 .00
ereveS 59 )%5.9(9 )%3.6(6 42 )%2.4(1 )%2.4(1
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Technical Notes
Eligibility Requirements
To participate in UDC, patients must receive
care in a federally funded HTC and meet at
least one of the following criteria: (1) have a
bleeding disorder due to congenital
deficiency or acquired inhibitors in which any
of the coagulation proteins is missing, re-
duced, or defective and has a functional level
of less than 50 %; or (2) have a diagnosis by
a physician of von Willebrand disease.
Individuals specifically excluded from
participation in UDC include persons with
any of the following: (1) an exclusive
diagnosis of a platelet disorder,
(2) thrombophilia, or (3) coagulation protein
deficiencies due to liver failure.
Data Collection
UDC data are collected during a participant's
"annual visit", which ideally should occur once
each calendar year (January-December),
with the interval between visits as close as
possible to 12 months. However,  partici-
pants under 2 years of age are encouraged
to be evaualated every 6 months until the age
of 2, and data are collected during these
visits according to guidelines and definitions
detailed in surveillance manuals provided to
HTC staff by CDC. Demographic information
and reasons for refusal are obtained using a
patient refusal form for all eligible people who
decline to participate. To protect patient
confidentiality, all data sent to CDC do not
contain personal identifying information, but
rather use a unique 12-digit code that is
generated by a computer software program
supplied to HTCs by CDC.
 Eligible participants are registered into UDC
through a registration form completed by
HTC staff; information collected on this form
includes patient demographic, diagnostic,
and historical information. Month and year of
birth are used to calculate age on the last day
of the current year. Information on race and
ethnicity is obtained from clinic records and
might be based either on self-report or on
observations made by care  providers. During
the annual visit, clinical information is
 recorded on a standardized data collection
form (annual visit form or baby visit form).  For
children under the age of two, information
about their birth; diagnostic testing; site of
blood draw; the type of treatment (episodic vs.
prophylactic); the presence and treatment of
inhibitors; the number of intracranial bleeding
episodes experienced; the type and brand
name of all factor concentrates or other treat-
ment products used; and whether or not
clotting factor is infused at home is collected.
Data are also recorded about the status of
vaccination against   hepatitis B; and among
patients with an intravenous access device,
the occurrence of a device-associated
infection.
All data collection forms are sent to CDC
where they are then key entered into a data-
base using double-entry software to minimize
data entry errors. Data are then screened for
omissions, inconsistencies, and unusual
values that possibly represent abstraction or
data-entry errors. Error reports are generated
and faxed to the HTC, where a designated
UDC contact uses available information to
resolve discrepancies and complete missing
data items.
Laboratory Testing
Blood specimens are not obtained from
participants under the age two, thus no labo-
ratory testing is preformed.
Mortality Reporting
Deaths occurring among all HTC patients
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(regardless of whether they have been
enrolled in UDC) are reported to CDC using a
mortality form. Data collected include age at
death, sex, race or ethnicity, type and severity
of disease, and whether or not blood products
had been used during the year prior to death.
Additionally, information about the death,
including the date, cause (primary and con-
tributing), and whether or not an autopsy was
performed, is also collected.
Tabulation and Presentation of Data
Data in this report are provisional. The data
represent the most current data available from
an on-going surveillance project. Future
reports will include expanded data tables to
cover subsequent surveillance periods and
will provide the results of more detailed
analyses of available data and findings from
special studies.
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  Treatment Center, Oklahoma City, OK
Fort Worth Comprehensive  Hemophilia
Center
  Ft. Worth, TX
North Texas Comprehensive Hemophilia
Center - Adult Program
  Dallas, TX
South Texas Comprehensive Hemophilia
Center
  San Antonio, TX
North Texas Comprehensive Hemophilia
Center - Pediatric Program
  Dallas, TX
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Region VII
Becky Dudley, L.C.S.W.
University of Iowa Hospitals and Clinics
  Iowa City, IA
Kansas City Regional Hemophilia Center
  Kansas City, MO
Nebraska Regional Hemophilia Treatment
Center
  Omaha, NE
Missouri/Illinois Regional Hemophilia Center
  St. Louis, MO
Center for Bleeding and Thrombotic Disor-
ders
  St. Louis, MO
Hemophilia Treatment Center
  Columbia, MO
Region VIII
Brenda Riske, M.S., M.B.A., M.P.A.
Mountain States Regional Hemophilia and
Thrombosis Center
  Denver, CO
Ted R. Montoya Hemophilia Center
  Albuquerque, NM
Mountain States Regional Hemophilia Center
  Tucson, AZ
Phoenix Children's Hospital
  Phoenix, AZ
Mountain States Regional Hemophilia Center
- Utah
  Salt Lake City, UT
Region IX
Judith Baker, M.H.S.A.
Children's Hospital of Los Angeles
  Los Angeles, CA
University of California
  San Diego, CA
Lucile Salter Packard Children's Hospital at
Stanford
  Palo Alto, CA
Alta Bates Medical Center
  Berkeley, CA
Hemophilia and Thrombosis Center of Hawaii
  Honolulu, HI
University of California at Davis
  Sacramento, CA
University of California, San Francisco
  San Francisco, CA
Orthopaedic Hospital of Los Angeles
  Los Angeles, CA
Children's Hospital, San Diego
  San Diego, CA
Children's Hospital of Orange County
  Orange, CA
Children's Hospital Oakland
  Oakland, CA
City of Hope National Medical Center
  Duarte, CA
Guam Comprehensive Hemophilia Care
  Program, Agana, GU
Valley Children's Hospital
  Madera, CA
Hemophilia and Thrombosis Center of Las
Vegas
  Las Vegas, NV
Region X
 Robina Ingram-Rich, R.N., M.S., M.P.H.
Puget Sound Blood Center and Program
  Seattle, WA
Oregon Hemophilia Treatment Center
  Portland, OR
Alaska Hemophilia Association
  Anchorage, AK
Idaho Regional Hemophilia Center
  Boise, ID
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Tom Abshire. M.D.
  Atlanta, GA
Randall Curtis, M.B.A
  Berkeley, CA
John Drake, R.N., M.S.N.
  Houston, TX
Nancy Duffy, R.N.
  Dayton, OH
Angela Forsyth, M.S., P.T.
  Philadelphia, PA
We would also like to acknowledge the assistance of the members
of the UDC Working Group
Nigel Key, M.D., F.R.C.P
  Chapel Hill, NC
Edward Kuebler, M.D.




  Atlanta, GA
Brenda Nielson, R.N., M.S.N.
  Chapel Hill, NC
Claire Phillipp, M.D.
  New Brunswick, NJ
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    Region IX
Puerto Rico & Virgin Is.
          Region II
Department of Health and Human Services
Centers for Disease Control and Prevention
*Location of regional core center.
